In this video, attorneys Jonathan E. Levitt, Esq. and Lucas W. Morgan, Esq. discuss what pharmacies should be aware of when appearing in front of a State Board of Pharmacy. Contact Frier Levitt today to speak to an... Read More
https://youtu.be/KqjA7M3yoH0 Attorneys Jonathan E. Levitt, Esq. and Lucas W. Morgan, Esq. discuss why pharmacies should be aware of when it comes to PBMs and Maximum Allowable Cost (MAC) laws, including: What is a MAC law? Challenging MAC... Read More
On July 12, 2019, the New York City Transit Authority (NYCTA) filed a Motion to extend the deadline to file its brief in opposition to Express Scripts' Motion to Dismiss the NYCTA's Complaint, or alternatively, to file an Amended Complaint.... Read More
A recent lawsuit filed by the New York City Transit Authority (NYCTA) raises important considerations for plan sponsors and agencies, such as the NYCTA, that retain the services of Pharmacy Benefits Managers (PBMs). On May 16, 2019, the NYCTA sued... Read More
Back on October 22, 2018, the state of Arkansas filed a petition for a writ of certiorari with the U.S. Supreme Court, asking them to review the U.S. Court of Appeals for the Eighth Circuit’s decision, specifically asking the Supreme Court to... Read More
Earlier this year, Attorney General Jeff Sessions announced the creation of a task force to pursue the makers and distributors of prescription opioids and his intention for the Justice Department to play a substantial role in supporting plaintiffs... Read More
Several States throughout the United States have passed laws regarding Maximum Allowable Cost (MAC) pricing and the corresponding appeals process. Some States have enacted legislation that is more favorable to independent pharmacies, than other... Read More
Several States throughout the United States have passed laws regarding Maximum Allowable Cost (MAC) pricing and the corresponding appeals process. In addition to enacting favorable MAC laws, some States such as Arkansas have afforded their resident... Read More
While some may still question whether it is true that "one bad apple can spoil the bunch," when it comes to doctors, group practices, and Medicare, this well-known adage is true. Surprisingly, there are instances when a single doctor's conduct, can... Read More
The impact of Direct and Indirect Remuneration ("DIR") fees on the specialty pharmacy industry cannot be overstated and has been widely reported in White Papers and industry news reports. However, the impact of DIR fees on the 340B sector is only... Read More
